Advertisement

Topics

Pharnext SAS Company Profile

10:42 EDT 20th September 2017 | BioPortfolio

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY©. The company identifies and develops synergic combinations of repositioned drugs at low dose. These PLEODRUG© might offer several key advantages: efficacy, safety, and robust intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.


News Articles [39 Associated News Articles listed on BioPortfolio]

Tasly, Pharnext form JV to develop Pharnext's PXT3003 in China

Concurrent with a €20mm ($21.8mm) equity investment in Pharnext SA, Tasly Pharmaceutical Co. Ltd. formed a 70/30 Tianjin-based joint venture with the French firm in which Tasly will own the majority...

Tasly/Pharnext JV licenses TCM combo compounds to ownership companies

Concurrent with its gaining rights to Pharnext SA's Phase III Charcot-Marie-Tooth disease Type 1A (CMT1A) compound (PXT3003), the 70/30 JV created by Tasly Pharmaceutical Co. Ltd. (majority owner) and...

Tasly Forges $22 Million Partnership with France's Pharnext

China's Tasly Pharma formed a partnership with Pharnext SA (Paris: ALPHA), a French company that combines and repositions approved drugs to develop innovative therapies. The agreement has three parts:...

Pharnext surge levels off as investors take in 20 million euro Chinese medicine deal

The rise in the share price of France’s neurodegenerative diseases specialist Pharnext has eased off…

Tasly, Pharnext Partner on Drug Combinations, Including lead Ph.III CMT1A Therapy

China’s Tasly Pharmaceutical Group is making a €20 million (approximately $22 million) investment in French biopharma Pharnext as part of the firms’ strategic partnership to discover and develop...

Tasly, Pharnext Partner on Drug Combinations, Including Lead Phase III CMT1A Therapy

China’s Tasly Pharmaceutical Group is making a €20 million (approximately $22 million) investment in French biopharma Pharnext as part of the firms’ strategic partnership to discover and develop...

DGAP-News: Pharnext präsentiert seine wegweisende PLEOTHERAPY F&E-Plattform auf der 6. Jahrestagung zur Neupositionierung von Medikamenten (deutsch)

Pharnext präsentiert seine wegweisende PLEOTHERAPY F&E-Plattform auf der 6. Jahrestagung zur Neupositionierung von Medikamenten DGAP-News: Pharnext S.A. / Schlagwort(e): Konferenz Pharnext präsent.....

Pharnext präsentiert auf der Alzheimer's Association International Conference 2017 Daten zu PXT864

Pflichtmitteilung: Pharnext SA (Paris:ALPHA) (FR00111911287 ALPHA), ein biopharmazeutisches Unternehmen und Vorreiter bei der Entwicklung von innovativen Arzneimitteln basierend auf der Kombinatio...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Pharnext SAS

Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. P...

More Information about "Pharnext SAS" on BioPortfolio

We have published hundreds of Pharnext SAS news stories on BioPortfolio along with dozens of Pharnext SAS Clinical Trials and PubMed Articles about Pharnext SAS for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharnext SAS Companies in our database. You can also find out about relevant Pharnext SAS Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record